Keywords: topotarget, curagen, start, first, nci-backed, pxd101, trial

TopoTarget and CuraGen start first NCI-backed PXD101 trial

Article | 03 April 2006

Print This

Denmark's TopoTarget A/S and CuraGen of the USA have announced the initiation of patient dosing in a new Phase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in